Christopher A. Luckhurst

Mission Therapeutics Ltd. Glenn Berge Building
Cambridge, ENG CB223FH, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 11 publications

Knockout or inhibition of USP30 protects dopaminergic neurons in a Parkinson's disease mouse model.

Knockout or inhibition of USP30 protects dopaminergic neurons in a Parkinson's disease mouse model.

Journal: Nature communications

Published: December 16, 2022

Identification of a Potent, Selective, and Brain-Penetrant Rho Kinase Inhibitor and its Activity in a Mouse Model of Huntington's Disease.

Identification of a Potent, Selective, and Brain-Penetrant Rho Kinase Inhibitor and its Activity in a Mouse Model of Huntington's Disease.

Journal: Journal of medicinal chemistry

Published: July 11, 2022

Evaluation of 5-(Trifluoromethyl)-1,2,4-oxadiazole-Based Class IIa HDAC Inhibitors for Huntington's Disease.

Evaluation of 5-(Trifluoromethyl)-1,2,4-oxadiazole-Based Class IIa HDAC Inhibitors for Huntington's Disease.

Journal: ACS medicinal chemistry letters

Published: October 12, 2020

Development and characterization of a CNS-penetrant benzhydryl hydroxamic acid class IIa histone deacetylase inhibitor.

Development and characterization of a CNS-penetrant benzhydryl hydroxamic acid class IIa histone deacetylase inhibitor.

Journal: Bioorganic & medicinal chemistry letters

Published: August 14, 2018

Potent, Selective, and CNS-Penetrant Tetrasubstituted Cyclopropane Class IIa Histone Deacetylase (HDAC) Inhibitors.

Potent, Selective, and CNS-Penetrant Tetrasubstituted Cyclopropane Class IIa Histone Deacetylase (HDAC) Inhibitors.

Journal: ACS medicinal chemistry letters

Published: July 30, 2015

Cathepsin C inhibitors: property optimization and identification of a clinical candidate.

Cathepsin C inhibitors: property optimization and identification of a clinical candidate.

Journal: Journal of medicinal chemistry

Published: March 06, 2014

Design, synthesis, and biological evaluation of potent and selective class IIa histone deacetylase (HDAC) inhibitors as a potential therapy for Huntington's disease.

Design, synthesis, and biological evaluation of potent and selective class IIa histone deacetylase (HDAC) inhibitors as a potential therapy for Huntington's disease.

Journal: Journal of medicinal chemistry

Published: November 23, 2013

Discovery and evolution of phenoxypiperidine hydroxyamide dual CCR3/H₁ antagonists. Part I.

Discovery and evolution of phenoxypiperidine hydroxyamide dual CCR3/H₁ antagonists. Part I.

Journal: Bioorganic & medicinal chemistry letters

Published: August 20, 2012

Discovery and evolution of phenoxypiperidine hydroxyamide dual CCR3/H₁ antagonists. Part II: optimising in vivo clearance.

Discovery and evolution of phenoxypiperidine hydroxyamide dual CCR3/H₁ antagonists. Part II: optimising in vivo clearance.

Journal: Bioorganic & medicinal chemistry letters

Published: August 20, 2012

Scaffold-hopping with zwitterionic CCR3 antagonists: identification and optimisation of a series with good potency and pharmacokinetics leading to the discovery of AZ12436092.

Scaffold-hopping with zwitterionic CCR3 antagonists: identification and optimisation of a series with good potency and pharmacokinetics leading to the discovery of AZ12436092.

Journal: Bioorganic & medicinal chemistry letters

Published: July 09, 2012

The discovery of CCR3/H1 dual antagonists with reduced hERG risk.

The discovery of CCR3/H1 dual antagonists with reduced hERG risk.

Journal: Bioorganic & medicinal chemistry letters

Published: July 09, 2012

Showing 1-11 of 11

Last Updated: 09/26/2026